Search

Your search keyword '"Herbst, R. S."' showing total 274 results
Start Over Author "Herbst, R. S."
274 results on '"Herbst, R. S."'

1. A mixture formulation of relativistic two-phase flow.

Author

Herbst, R. S. and Zeidan, D.

Subjects
*MIXTURES, *SPEED limits, *EULER equations
Abstract

In this paper compressible two-phase flow is investigated in the relativistic framework. The mixture variables are defined in terms of the relativistic variables rather than their classical counterparts. We consider the case of a single phase, common pressure as well as a mixture pressure. The equations are shown to reduce to their respective non-relativistic and single-phase limits for slow speeds and negligible pressure contribution. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Author

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., Lynch, T. J., Schlessinger, J., Lee, J., Lifton, R. P., Wistuba, I. I., and Herbst, R. S.

Published
2017
Full Text
View/download PDF

14. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Author

Gettinger, S. N., primary, Choi, J., additional, Mani, N., additional, Sanmamed, M. F., additional, Datar, I., additional, Sowell, Ryan, additional, Du, Victor Y., additional, Kaftan, E., additional, Goldberg, S., additional, Dong, W., additional, Zelterman, D., additional, Politi, K., additional, Kavathas, P., additional, Kaech, S., additional, Yu, X., additional, Zhao, H., additional, Schlessinger, J., additional, Lifton, R., additional, Rimm, D. L., additional, Chen, L., additional, Herbst, R. S., additional, and Schalper, K. A., additional

Published
2018
Full Text
View/download PDF

16. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Author

Herbst, R S, Baas, P, Perez-Gracia, J L, Felip, E, Kim, D -W, Han, J -Y, Molina, J R, Kim, J -H, Arvis, C Dubos, Ahn, M -J, Majem, M, Fidler, M J, Surmont, V, Castro, G de, Garrido, M, Shentu, Y, Emancipator, K, Samkari, A, Jensen, E H, and Lubiniecki, G M

Subjects
*SURVIVAL analysis (Biometry), *NON-small-cell lung carcinoma, *SIMULATED patients
Abstract

Background In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data. Patients and methods PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) ≥50% and ≥1%; pembrolizumab doses were pooled in this analysis. Results At date cut-off of 24 March 2017, median follow-up was 31 months (range 23–41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS ≥50%. For TPS ≥50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS ≥1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS ≥50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS ≥1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)]. Conclusion Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples. Trial registration ClinicalTrials.gov: NCT01905657. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

17. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Author

Davis, D. W., Takamori, R., Raut, C. P., Xiong, H. Q., Herbst, R. S., Stadler, W. M., Heymach, J. V., Demetri, G. D., Rashid, A., Shen, Y., Sijin Wen, Abbruzzese, J. L., and Mcconkey, D. J.

Subjects
Cancer Research, Oncology
Abstract

Purpose: To determine the effects of small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR)-2 (SU5416 and SU6668) on receptor phosphorylation in tumor xenografts and in paired tumor biopsies obtained in three clinical trials in patients with advanced solid malignancies. Experimental Design: The dose-dependent effects of SU6668 on angiogenesis and tumor growth were investigated in orthotopic L3.6pl pancreatic tumors. Excisional or 18G core biopsies were obtained from patients before and after therapy with SU5416 or SU6668. Laser scanning cytometry–mediated analysis was used to quantify levels of phosphorylated and total VEGFRs and platelet-derived growth factor receptors (PDGFR), tumor microvessel densities, vessel sizes, and endothelial and tumor cell apoptosis. Results: Significant inhibition of tumor microvessel density and growth and increased apoptosis were observed at SU6668 maximum tolerated dose (100 mg/kg) in L3.6pl xenografts. At 6 hours post therapy, SU6668 reduced VEGFR and PDGFR phosphorylation in the tumors by 50% and 92%, respectively, but levels rebounded beyond the baselines by 24 hours. Levels of phosphorylated VEGFR-2 and PDGFR also decreased significantly (≈50%) 6 hours after therapy in 1 of 6 primary human tumors treated with SU6668, but these effects were not associated with increased apoptosis. A significant increase in endothelial cell apoptosis was observed in one tumor exposed to SU5416 and was associated with an increase in vessel size, but these changes occurred without an increase in tumor cell death. Conclusions: SU5416 and SU6668 displayed biological activity in xenografts. However, neither drug produced marked biological activity in primary patient tumors.

Published
2005
Full Text
View/download PDF

19. On the Relation of Isothermal Collape to Steady Bondi-Accretion.

Author

Herbst, R. S., Harley, C., and Momoniat, E.

Subjects
*COMPUTER simulation, *CONSERVATION laws (Mathematics), *HYPERBOLIC differential equations, *PROTOSTARS, *FINITE volume method
Abstract

In this paper numerical simulations of collapsing, spherically symmetric, isothermal clouds is revisited. Two models have been considered: initially uniform clouds and initially perturbed Bonnor-Ebert spheres, both of which are embedded in a less dense environment. A finite volume method employing the Marquina flux is used to solve the hyperbolic conservation laws governing the collapse. Combining the numerical results with the analytical results for steady-state Bondi accretion we have shown that the mass of the nascent protostar and the accretion rate onto the protostar can be found directly from the analytical solutions. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

23. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Author

Kozloff, M F, primary, Martin, L P, additional, Krzakowski, M, additional, Samuel, T A, additional, Rado, T A, additional, Arriola, E, additional, De Castro Carpeño, J, additional, Herbst, R S, additional, Tarazi, J, additional, Kim, S, additional, Rosbrook, B, additional, Tortorici, M, additional, Olszanski, A J, additional, and Cohen, R B, additional

Published
2012
Full Text
View/download PDF

25. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

Author

Infante, J. R., primary, Kurzrock, R., additional, Spratlin, J., additional, Burris, H. A., additional, Eckhardt, S. G., additional, Li, J., additional, Wu, K., additional, Skolnik, J. M., additional, Hylander-Gans, L., additional, Osmukhina, A., additional, Huszar, D., additional, and Herbst, R. S., additional

Published
2011
Full Text
View/download PDF

27. Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.

Author

Soulieres, D., primary, Wolf, J., additional, Shepherd, F. A., additional, Cappuzzo, F., additional, Bunn, P. A., additional, Herbst, R. S., additional, Hirsch, F. R., additional, Kerr, K. M., additional, Mitsudomi, T., additional, Tsao, M. S., additional, Yang, C., additional, Richardson, F. C., additional, Klughammer, B., additional, Wacker, B., additional, Sternberg, D., additional, and Davies, A. M., additional

Published
2011
Full Text
View/download PDF

28. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.

Author

Komaki, R., primary, Blumenschein, G. R., additional, Wistuba, I. I., additional, Lee, J. J., additional, Allen, P., additional, Wei, X., additional, Welsh, J., additional, O'Reilly, M., additional, Herbst, R. S., additional, Tang, X., additional, Meyn, R., additional, Liu, D., additional, and Hong, W. K., additional

Published
2011
Full Text
View/download PDF

42. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program

Author

Kim, E. S., primary, Herbst, R. S., additional, Lee, J. J., additional, Blumenschein, G., additional, Tsao, A., additional, Wistuba, I., additional, Alden, C., additional, Gupta, S., additional, Stewart, D., additional, and Hong, W. K., additional

Published
2009
Full Text
View/download PDF

48. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study

Author

Tran, H. T., primary, Kim, E. S., additional, Lee, J. J., additional, Herbst, R. S., additional, Liu, S., additional, Wistuba, I. I., additional, Yan, S., additional, Mao, L., additional, Hong, W. K., additional, and Heymach, J. V., additional

Published
2008
Full Text
View/download PDF

49. Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone

Author

Dang, T. P., primary, Salmon, J. S., additional, Chen, H., additional, Chen, S., additional, Lee, J. W., additional, Sandler, A. B., additional, Herbst, R. S., additional, Brahmer, J., additional, Carbone, D. P., additional, and Shyr, Y., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results